An overview of conceptual frameworks, analytical approaches of the gastric cancer treatment market is the main objective of the report, which further consist the market opportunity and insights of the data involved in the making of the respective market. The gastric cancer treatment market is expected to grow at a faster rate in the near future.
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.
The global gastric cancer treatment market in 2020 is estimated for more than US$ 3.2 Bn and expected to reach a value of US$ 10.6 Bn by 2028 with a significant CAGR of 16.0%.
The global gastric cancer treatment market is driven by the increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the globe. For instance, according to data published by World Health Organization (WHO), in September 2018, Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 Mn deaths in 2018. Around 1 in 6 deaths are happening due to cancer worldwide. In addition, increased usage of combination therapies is one of the major factors boosting the growth of the global gastric cancer treatment market.
Furthermore, a large number of regulatory approvals for metastatic gastric cancer are expected to augment growth of the global market over the forecast period. Moreover, the use of low-dose radiation technology-based devices worldwide is fueling the growth of the global market across the globe.
However, the high cost of therapy and lack of sufficient financial support from health insurance policies across the globe are factors that hamper the growth of the global market. Also, various factors that are anticipated to restraint growth of the global market includes strict monitoring processes for approving complicated nature of radiation devices and less availability of commercial drugs for the treatment of stomach cancer globally.
Nevertheless, the introduction of premium-priced treatment for the advanced or metastatic disease, such as anti-angiogenesis and HER2-targeted therapies in the global market, are expected to create opportunities for growth of the global market over the forecast period.
Gastric cancer treatment market is segmented on the basis of type of treatment, end-user, and by region.
Surgery
Chemo Therapy
Adjuvant Chemotherapy
Targeted Drugs Therapy
Sunitinib (Sutent)
Trastuzumab (Herceptin)
Imatinib (Gleevec)
Radiation Therapy
Hospitals
Clinics
Specialized Cancer Treatment Centers
Ambulatory Surgical Centers
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
In the global gastric cancer treatment market, 10 numbers drugs are listed below which are approved by the FDA in 2019. Three different drug combinations are used in gastric cancer treatment. Combinations of drugs usually work in better way than single drugs because different drugs kill cancer cells in different ways. FU-LV, TPF, XELIRI are the three different drug combinations. Each drug in this combination is approved by the Food and Drug Administration (FDA) to treat gastric cancer or conditions related to cancer.
Source: National Cancer Institute, 2019
Some of the key participating players in global gastric cancer treatment market are Biogen, Inc., Eli Lilly and company, Otsuka Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis International AG, GlaxoSmithKline plc, and Merck KGaA.
On the basis of region, the gastric cancer treatment market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
1. Global Gastric Cancer Treatment Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Gastric Cancer Treatment Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Gastric Cancer Treatment Market Snapshot
2.4. Global Gastric Cancer Treatment Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Gastric Cancer Treatment Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Gastric Cancer Treatment Market, By Type of Treatment
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Type of Treatment
3.1.2. BPS Analysis, By Type of Treatment
3.2. Market Revenue (US$Mn) Forecast, By Type of Treatment
3.2.1. Surgery
3.2.2. Chemo Therapy
3.2.3. Adjuvant Chemotherapy
3.2.4. Targeted Drugs Therapy
3.2.4.1. Sunitinib (Sutent)
3.2.4.2. Trastuzumab (Herceptin)
3.2.4.3. Imatinib (Gleevec)
3.2.5. Radiation Therapy
3.3. Global Gastric Cancer Treatment Market Attractiveness Index, By Type of Treatment
4. Global Gastric Cancer Treatment Market, By End User
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By End User
4.1.2. BPS Analysis, By End User
4.2. Market Revenue (US$Mn) Forecast, By End User
4.2.1. Hospitals
4.2.2. Clinics
4.2.3. Specialized Cancer Treatment Centers
4.2.4. Ambulatory Surgical Centers
4.3. Global Gastric Cancer Treatment Market Attractiveness Index, By End User
5. Global Gastric Cancer Treatment Market, By Region
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Region
5.1.2. BPS Analysis, By Region
5.2. Market Revenue (US$Mn) Forecast, By Region
5.2.1. North America
5.2.2. Latin America
5.2.3. Europe
5.2.4. Asia Pacific
5.2.5. Middle East
5.2.6. Africa
5.3. Global Gastric Cancer Treatment Market Attractiveness Index, By Region
6. North America Gastric Cancer Treatment Market Analysis and Forecast, 2020–2028
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Country
6.1.2. BPS Analysis, By Country
6.2. Market Revenue (US$Mn) Forecast, By Country
6.2.1. U.S. Gastric Cancer Treatment Market
6.2.2. Canada Gastric Cancer Treatment Market
6.3. North America Gastric Cancer Treatment Market, By Type of Treatment
6.3.1. Surgery
6.3.2. Chemo Therapy
6.3.3. Adjuvant Chemotherapy
6.3.4. Targeted Drugs Therapy
6.3.4.1. Sunitinib (Sutent)
6.3.4.2. Trastuzumab (Herceptin)
6.3.4.3. Imatinib (Gleevec)
6.3.5. Radiation Therapy
6.4. North America Gastric Cancer Treatment Market, By End User
6.4.1. Hospitals
6.4.2. Clinics
6.4.3. Specialized Cancer Treatment Centers
6.4.4. Ambulatory Surgical Centers
6.5. North America Gastric Cancer Treatment Market Attractiveness Index
6.5.1. By Country
6.5.2. By Type of Treatment
6.5.3. By End User
7. Latin America Gastric Cancer Treatment Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market (US$Mn) Forecast, By Country
7.2.1. Brazil Gastric Cancer Treatment Market
7.2.2. Mexico Gastric Cancer Treatment Market
7.2.3. Argentina Gastric Cancer Treatment Market
7.2.4. Rest of Latin America Gastric Cancer Treatment Market
7.3. Latin America Gastric Cancer Treatment Market, By Type of Treatment
7.3.1. Surgery
7.3.2. Chemo Therapy
7.3.3. Adjuvant Chemotherapy
7.3.4. Targeted Drugs Therapy
7.3.4.1. Sunitinib (Sutent)
7.3.4.2. Trastuzumab (Herceptin)
7.3.4.3. Imatinib (Gleevec)
7.3.5. Radiation Therapy
7.4. Latin America Gastric Cancer Treatment Market, By End User
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Specialized Cancer Treatment Centers
7.4.4. Ambulatory Surgical Centers
7.5. Latin America Gastric Cancer Treatment Market Attractiveness Index
7.5.1. By Country
7.5.2. By Type of Treatment
7.5.3. By End User
8. Europe Gastric Cancer Treatment Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. U.K. Gastric Cancer Treatment Market
8.2.2. Germany Gastric Cancer Treatment Market
8.2.3. Italy Gastric Cancer Treatment Market
8.2.4. France Gastric Cancer Treatment Market
8.2.5. Spain Gastric Cancer Treatment Market
8.2.6. Russia Gastric Cancer Treatment Market
8.2.7. Poland Gastric Cancer Treatment Market
8.2.8. BENELUX Gastric Cancer Treatment Market
8.2.9. NORDIC Gastric Cancer Treatment Market
8.2.10. Rest of Europe Gastric Cancer Treatment Market
8.3. Europe Gastric Cancer Treatment Market, By Type of Treatment
8.3.1. Surgery
8.3.2. Chemo Therapy
8.3.3. Adjuvant Chemotherapy
8.3.4. Targeted Drugs Therapy
8.3.4.1. Sunitinib (Sutent)
8.3.4.2. Trastuzumab (Herceptin)
8.3.4.3. Imatinib (Gleevec)
8.3.5. Radiation Therapy
8.4. Europe Gastric Cancer Treatment Market, By End User
8.4.1. Hospitals
8.4.2. Clinics
8.4.3. Specialized Cancer Treatment Centers
8.4.4. Ambulatory Surgical Centers
8.5. Europe Gastric Cancer Treatment Market Attractiveness Index
8.5.1. By Country
8.5.2. By Type of Treatment
8.5.3. By End User
9. Asia Pacific Gastric Cancer Treatment Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. China Gastric Cancer Treatment Market
9.2.2. India Gastric Cancer Treatment Market
9.2.3. Japan Gastric Cancer Treatment Market
9.2.4. Australia and New Zealand Gastric Cancer Treatment Market
9.2.5. South Korea Gastric Cancer Treatment Market
9.2.6. ASEAN Gastric Cancer Treatment Market
9.2.7. Rest of Asia Pacific Gastric Cancer Treatment Market
9.3. Asia Pacific Gastric Cancer Treatment Market, By Type of Treatment
9.3.1. Surgery
9.3.2. Chemo Therapy
9.3.3. Adjuvant Chemotherapy
9.3.4. Targeted Drugs Therapy
9.3.4.1. Sunitinib (Sutent)
9.3.4.2. Trastuzumab (Herceptin)
9.3.4.3. Imatinib (Gleevec)
9.3.5. Radiation Therapy
9.4. Asia Pacific Gastric Cancer Treatment Market, By End User
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Specialized Cancer Treatment Centers
9.4.4. Ambulatory Surgical Centers
9.5. Asia Pacific Gastric Cancer Treatment Market Attractiveness Index
9.5.1. By Country
9.5.2. By Type of Treatment
9.5.3. By End User
10. Middle East Gastric Cancer Treatment Market, By Region
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. GCC Countries Gastric Cancer Treatment Market
10.2.2. Israel Gastric Cancer Treatment Market
10.2.3. Oman Gastric Cancer Treatment Market
10.2.4. Rest of Middle East Gastric Cancer Treatment Market
10.3. Middle East Gastric Cancer Treatment Market, By Type of Treatment
10.3.1. Surgery
10.3.2. Chemo Therapy
10.3.3. Adjuvant Chemotherapy
10.3.4. Targeted Drugs Therapy
10.3.4.1. Sunitinib (Sutent)
10.3.4.2. Trastuzumab (Herceptin)
10.3.4.3. Imatinib (Gleevec)
10.3.5. Radiation Therapy
10.4. Middle East Gastric Cancer Treatment Market, By End User
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Specialized Cancer Treatment Centers
10.4.4. Ambulatory Surgical Centers
10.5. Middle East Gastric Cancer Treatment Market Attractiveness Index
10.5.1. By Country
10.5.2. By Type of Treatment
10.5.3. By End User
11. Africa Gastric Cancer Treatment Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. South Africa Gastric Cancer Treatment Market
11.2.2. Egypt Gastric Cancer Treatment Market
11.2.3. North Africa Gastric Cancer Treatment Market
11.2.4. Rest of Africa Gastric Cancer Treatment Market
11.3. Africa Gastric Cancer Treatment Market, By Type of Treatment
11.3.1. Surgery
11.3.2. Chemo Therapy
11.3.3. Adjuvant Chemotherapy
11.3.4. Targeted Drugs Therapy
11.3.4.1. Sunitinib (Sutent)
11.3.4.2. Trastuzumab (Herceptin)
11.3.4.3. Imatinib (Gleevec)
11.3.5. Radiation Therapy
11.4. Africa Gastric Cancer Treatment Market, By End User
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Specialized Cancer Treatment Centers
11.4.4. Ambulatory Surgical Centers
11.5. Africa Gastric Cancer Treatment Market Attractiveness Index
11.5.1. By Country
11.5.2. By Type of Treatment
11.5.3. By End User
12. Recommendation
12.1. Market Strategy
13. Competitive Landscape
13.1. Competition Dashboard
13.2. List and Company Overview of Global Key Players
13.3. Company Profiles
13.3.1. Biogen, Inc.
13.3.1.1. Company Overview
13.3.1.2. Financial Overview
13.3.1.3. Product Portfolio
13.3.1.4. Key Developments
13.3.1.5. Business Strategies
13.3.2. Eli Lilly and company
13.3.3. Otsuka Holdings Co. Ltd.
13.3.4. F. Hoffmann-La Roche Ltd.
13.3.5. Novartis International AG
13.3.6. GlaxoSmithKline plc
13.3.7. Merck KGaA
14. Acronyms
